View : 139 Download: 0
One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects
- Title
- One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects
- Authors
- Lovell; Jonathan F.; Miura; Kazutoyo; Baik; Yeong Ok; Lee; Chankyu; Jeong-Yoon; Park; Young-Shin; Hong; Ingi; Jung Hyuk; Kim; Taewoo; Seo; Sang Hwan; Jae-Ouk; Song; Manki; Chung-Jong; Choi; Jae-Ki; Jieun; Choo; Eun Ju; Jung-Hyun
- Ewha Authors
- 김충종
- SCOPUS Author ID
- 김충종
- Issue Date
- 2024
- Journal Title
- International Journal of Infectious Diseases
- ISSN
- 1201-9712
- Citation
- International Journal of Infectious Diseases vol. 138, pp. 73 - 80
- Keywords
- COVID-19; Durability; Humoral immunity; Liposome; RBD; SARS-CoV-2; Vaccine
- Publisher
- Elsevier B.V.
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Objective: EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization. The objective of this study was to determine the longer-term antibody response of the vaccine. Methods: To assess immunogenicity 6 and 12 months after vaccination, participants in the Phase 2 trial (NCT04783311) were excluded if they: 1) withdrew, 2) reported COVID-19 infection or additional vaccination, or 3) exhibited increasing Spike (S) antibodies (representing possible non-reported infection). Following exclusions, of the 197 initial subjects, anti-S IgG antibodies and neutralizing antibodies were further assessed in 124 subjects at the 6-month timepoint, and 36 subjects at the 12-month timepoint. Results: Median anti-S antibody half-life was 52 days (interquartile range [IQR]:42-70), in the “early” period from 3 weeks to 6 months, and 130 days (IQR:97-169) in the “late” period from 6 to 12 months. There was a negative correlation between initial antibody titer and half-life. Anti-S and neutralizing antibody responses were correlated. Neutralizing antibody responses showed longer half-lives; the early period had a median half-life of 120 days (IQR:81-207), and the late period had a median half-life of 214 days (IQR:140-550). Conclusion: These data establish antibody durability of ECV-19, using a framework to analyze COVID-19 vaccine-induced antibodies during periods of high infection. © 2023 The Author(s)
- DOI
- 10.1016/j.ijid.2023.11.004
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML